Since PRL is recognized as a biomarker (93, 100), poor prognosis marker (95), risk factor (49, 105–107), and has even been proposed as a potential therapeutic target (2, 43) for EC, it would be fascinating to carry out clinical studies in which the interaction of PRL with PRLR is blocked to confirm the evidence shown by the various working groups that propose PRL as a critical factor in the progression of this type of neoplasia. This evidence concerns the gene PRL and neoplasm.